Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
11
11
2018
pubmed:
21
4
2019
medline:
19
12
2019
entrez:
21
4
2019
Statut:
ppublish
Résumé
Preoperative factors that reliably predict lymph node (LN) metastases in pancreatic neuroendocrine tumors (PanNETs) are unclear. The number of LNs needed to accurately stage PanNETs has not been defined. Patients who underwent curative-intent resection of non-functional PanNETs at eight institutions from 2000 to 2016 were analyzed. Preoperative factors associated with LN metastases were identified. A procedure-specific target for LN retrieval to accurately stage patients was determined. Of 695 patients who underwent resection, 33% of tumors were proximal (head/uncinate) and 67% were distal (neck/body/tail). Twenty-six percent of patients (n = 158) had LN-positive disease, which was associated with a worse 5-year recurrence-free survival (RFS; 60% vs. 86%; p < 0.001). The increasing number of positive LNs was not associated with worse RFS. Preoperative factors associated with positive LNs included tumor size ≥ 2 cm (odds ratio [OR] 6.6; p < 0.001), proximal location (OR 2.5; p < 0.001), moderate versus well-differentiation (OR 2.1; p = 0.006), and Ki-67 ≥ 3% (OR 3.1; p < 0.001). LN metastases were also present in tumors without these risk factors: < 2 cm (9%), distal location (19%), well-differentiated (23%), and Ki-67 < 3% (16%). Median LN retrieval was 13 for pancreatoduodenectomy (PD), but only 9 for distal pancreatectomy (DP). Given that PD routinely includes a complete regional lymphadenectomy, a minimum number of LNs to accurately stage patients was not identified. However, for DP, removal of less than seven LNs failed to discriminate 5-year RFS between LN-positive and LN-negative patients (less than seven LNs: 72% vs. 83%, p = 0.198; seven or more LNs: 67% vs. 86%; p = 0.002). Tumor size ≥ 2 cm, proximal location, moderate differentiation, and Ki-67 ≥ 3% are preoperative factors that predict LN positivity in resected non-functional PanNETs. Given the 9-23% incidence of LN metastases in patients without such risk factors, routine regional lymphadenectomy should be considered. PD inherently includes sufficient LN retrieval, while DP should aim to remove seven or more LNs for accurate staging.
Sections du résumé
BACKGROUND
BACKGROUND
Preoperative factors that reliably predict lymph node (LN) metastases in pancreatic neuroendocrine tumors (PanNETs) are unclear. The number of LNs needed to accurately stage PanNETs has not been defined.
METHODS
METHODS
Patients who underwent curative-intent resection of non-functional PanNETs at eight institutions from 2000 to 2016 were analyzed. Preoperative factors associated with LN metastases were identified. A procedure-specific target for LN retrieval to accurately stage patients was determined.
RESULTS
RESULTS
Of 695 patients who underwent resection, 33% of tumors were proximal (head/uncinate) and 67% were distal (neck/body/tail). Twenty-six percent of patients (n = 158) had LN-positive disease, which was associated with a worse 5-year recurrence-free survival (RFS; 60% vs. 86%; p < 0.001). The increasing number of positive LNs was not associated with worse RFS. Preoperative factors associated with positive LNs included tumor size ≥ 2 cm (odds ratio [OR] 6.6; p < 0.001), proximal location (OR 2.5; p < 0.001), moderate versus well-differentiation (OR 2.1; p = 0.006), and Ki-67 ≥ 3% (OR 3.1; p < 0.001). LN metastases were also present in tumors without these risk factors: < 2 cm (9%), distal location (19%), well-differentiated (23%), and Ki-67 < 3% (16%). Median LN retrieval was 13 for pancreatoduodenectomy (PD), but only 9 for distal pancreatectomy (DP). Given that PD routinely includes a complete regional lymphadenectomy, a minimum number of LNs to accurately stage patients was not identified. However, for DP, removal of less than seven LNs failed to discriminate 5-year RFS between LN-positive and LN-negative patients (less than seven LNs: 72% vs. 83%, p = 0.198; seven or more LNs: 67% vs. 86%; p = 0.002).
CONCLUSIONS
CONCLUSIONS
Tumor size ≥ 2 cm, proximal location, moderate differentiation, and Ki-67 ≥ 3% are preoperative factors that predict LN positivity in resected non-functional PanNETs. Given the 9-23% incidence of LN metastases in patients without such risk factors, routine regional lymphadenectomy should be considered. PD inherently includes sufficient LN retrieval, while DP should aim to remove seven or more LNs for accurate staging.
Identifiants
pubmed: 31004295
doi: 10.1245/s10434-019-07367-y
pii: 10.1245/s10434-019-07367-y
pmc: PMC10181829
mid: NIHMS1887050
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2517-2524Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1TR000454
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR000456
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000454
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1TR000456
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Eur J Surg Oncol. 2018 Jan;44(1):148-156
pubmed: 29198492
Medicine (Baltimore). 2018 Mar;97(13):e0185
pubmed: 29595652
Surgery. 2013 Oct;154(4):785-91; discussion 791-3
pubmed: 24074416
JAMA Surg. 2013 Oct;148(10):932-9
pubmed: 23986355
Am J Clin Oncol. 2013 Aug;36(4):325-30
pubmed: 22547011
Int J Colorectal Dis. 2009 Nov;24(11):1297-302
pubmed: 19479270
Arch Surg. 2011 May;146(5):534-8
pubmed: 21576607
Clin Cancer Res. 2008 Dec 1;14(23):7798-803
pubmed: 19047107
Ann Oncol. 2008 May;19(5):903-8
pubmed: 18209014
Gastroenterology. 2008 Nov;135(5):1469-92
pubmed: 18703061
Ann Surg. 2008 Mar;247(3):490-500
pubmed: 18376195
World J Gastrointest Surg. 2012 Jan 27;4(1):9-19
pubmed: 22347537
Eur J Surg Oncol. 2008 Feb;34(2):159-65
pubmed: 17566691
Mod Pathol. 2010 Jun;23(6):824-33
pubmed: 20305616
World J Surg. 2002 Oct;26(10):1267-71
pubmed: 12205558
Iran J Pathol. 2015 Spring;10(2):127-35
pubmed: 26351473
Eur J Surg Oncol. 2017 Aug;43(8):1456-1462
pubmed: 28576463
J Surg Oncol. 2016 Sep;114(4):440-5
pubmed: 27334541
Ann Surg. 2014 Feb;259(2):197-203
pubmed: 24253141
Ann Oncol. 2005 Nov;16(11):1806-10
pubmed: 16085691
J Clin Oncol. 2003 Aug 1;21(15):2912-9
pubmed: 12885809
Ann Surg. 2012 Aug;256(2):321-5
pubmed: 22415420
J Clin Oncol. 2005 Oct 1;23(28):7114-24
pubmed: 16192595
Eur J Surg Oncol. 2017 Dec;43(12):2349-2356
pubmed: 28943179
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Gastric Cancer. 2013 Jul;16(3):309-17
pubmed: 22945599
World J Surg. 2000 Nov;24(11):1312-8
pubmed: 11038199
PLoS One. 2015 Jul 08;10(7):e0129531
pubmed: 26154617
J Clin Oncol. 2002 Jun 1;20(11):2633-42
pubmed: 12039924
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848